Literature DB >> 30051926

Intranasal immunization with recombinant chlamydial protease-like activity factor attenuates atherosclerotic pathology following Chlamydia pneumoniae infection in mice.

Weidang Li1, Pareesha Gudipaty2, Chuxi Li3,4, Kyle K Henderson3, Kyle H Ramsey1,3, Ashlesh K Murthy1.   

Abstract

We have shown previously that intranasal vaccination with recombinant chlamydial protease-like activity factor (rCPAF: antigen) and interleukin-12 (IL-12) as an adjuvant induces robust protection against pathological consequences of female genital tract infection with Chlamydia muridarum, a closely related species and a rodent model for the human pathogen Chlamydia trachomatis. Another related species Chlamydia pneumoniae, a human respiratory pathogen, has been associated with exacerbation of atherosclerotic pathology. CPAF is highly conserved among Chlamydia spp. leading us to hypothesize that immunization with rCPAF with IL-12 will protect against high-fat diet (HFD) and C. pneumoniae-induced acceleration of atherosclerosis. rCPAF ± IL-12 immunization induced robust splenic antigen (Ag)-specific IFN-γ and TNF-α production and significantly elevated serum total anti-CPAF Ab, IgG2c, and IgG1 antibody levels compared to mock or IL-12 alone groups. The addition of IL-12 to rCPAF significantly elevated splenic Ag-specific IFN-γ production and IgG2c/IgG1 anti-CPAF antibody ratio. Following intranasal C. pneumoniae challenge and HFD feeding, rCPAF ± IL-12-immunized mice displayed significantly enhanced splenic IFN-γ, not TNF-α, response on days 6 and 9 after challenge, and significantly reduced lung chlamydial burden on day 9 post-challenge compared to mock- or IL-12-immunized mice. Importantly, rCPAF ± IL-12-immunized mice displayed significantly reduced atherosclerotic pathology in the aortas after C. pneumoniae challenge. Serum cholesterol levels were comparable between the groups suggesting that the observed differences in pathology were due to protective immunity against the infection. Together, these results confirm and extend our previous observations that CPAF is a promising candidate antigen for a multisubunit vaccine regimen to protect against Chlamydia-induced pathologies, including atherosclerosis.
© 2018 Australasian Society for Immunology Inc.

Entities:  

Keywords:  zzm321990Chlamydia pneumoniaezzm321990; Chlamydial protease-like activity factor; atherosclerosis; protective immunity

Mesh:

Substances:

Year:  2018        PMID: 30051926      PMCID: PMC6338504          DOI: 10.1111/imcb.12192

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  30 in total

1.  Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge.

Authors:  Weidang Li; Ashlesh K Murthy; M Neal Guentzel; James P Chambers; Thomas G Forsthuber; J Seshu; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2010-07-06       Impact factor: 3.441

2.  Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.

Authors:  Ashlesh K Murthy; James P Chambers; Patricia A Meier; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

3.  The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cells.

Authors:  Cathi Murphey; Ashlesh K Murthy; Patricia A Meier; M Neal Guentzel; Guangming Zhong; Bernard P Arulanandam
Journal:  Cell Immunol       Date:  2006-11-20       Impact factor: 4.868

4.  Chlamydia pneumoniae and progression of subclinical atherosclerosis.

Authors:  Marty S Player; Arch G Mainous; Charles J Everett; Vanessa A Diaz; Michele E Knoll; Robert U Wright
Journal:  Eur J Prev Cardiol       Date:  2012-12-19       Impact factor: 7.804

5.  Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge.

Authors:  Bharat K R Chaganty; Ashlesh K Murthy; Shankar J Evani; Weidang Li; M Neal Guentzel; James P Chambers; Guangming Zhong; Bernard P Arulanandam
Journal:  Vaccine       Date:  2010-01-05       Impact factor: 3.641

6.  Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection.

Authors:  Weidang Li; Ashlesh K Murthy; M Neal Guentzel; J Seshu; Thomas G Forsthuber; Guangming Zhong; Bernard P Arulanandam
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

7.  Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis.

Authors:  J T Grayston; M B Aldous; A Easton; S P Wang; C C Kuo; L A Campbell; J Altman
Journal:  J Infect Dis       Date:  1993-11       Impact factor: 5.226

8.  CD8+ T cells mediate Chlamydia pneumoniae-induced atherosclerosis in mice.

Authors:  Mark T Zafiratos; Srikanth Manam; Kyle K Henderson; Kyle H Ramsey; Ashlesh K Murthy
Journal:  Pathog Dis       Date:  2015-07-27       Impact factor: 3.166

Review 9.  Animal models for Chlamydia pneumoniae infection.

Authors:  P Saikku; K Laitinen; M Leinonen
Journal:  Atherosclerosis       Date:  1998-10       Impact factor: 5.162

10.  Atherosclerosis Induced by Chlamydophila pneumoniae: A Controversial Theory.

Authors:  Hamidreza Honarmand
Journal:  Interdiscip Perspect Infect Dis       Date:  2013-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.